Drug-eluting stents: From bench to bed

Cardiovascular Radiation Medicine

Volumn 3, Issue 3-4, 2002, Pages 226-241

  Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Radiation; Restenosis; Stents

Indexed keywords

ABT 578; ANTIINFLAMMATORY AGENT; BETA1 INTERFERON; CYCLOSPORIN; DACTINOMYCIN; DEXAMETHASONE; EVEROLIMUS; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID; PACLITAXEL; POLYMER; RAPAMYCIN; TACROLIMUS; TRANILAST;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA; CLINICAL TRIAL; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; CYTOSTASIS; DELAYED DRUG RELEASE; DEVICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG RELEASE; HUMAN; IMPLANTABLE PORT SYSTEM; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; RESTENOSIS; REVIEW;

EID: 0142227737     PISSN: 15221865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1522-1865(03)00115-X     Document Type: Review

References (100)

1. Sigwart U., Puel J., Mirkovitch V., Joffre F., Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl Med. 316:1987;701-706.
2. Roubin G.S., Cannon A.D., Agrawal S.K., Macander P.J., Dean L.S., Baxley W.A., Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 85:1992;916-927.
3. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501.
4. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emanuelsson H., Marco J., Legrand V., Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
5. Lafont A., Guzman L.A., Whitlow P.L., Goormastic M., Cornhill J.F., Chisolm G.M. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res. 76(6):1995;996-1002.
6. Mintz G.S., Popma J.J., Pichard A.D., Kent K.M., Satler L.F., Wong C., Hong M.K., Kovach J.A., Leon M.B. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 94:1996;35-43.
7. Leon M., Baim D., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., Giambartolomei A., Diver D.J., Lasorda D.M., Williams D.O., Pocock S.J., Kuntz R.E. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med. 339:1998;1665-1671.
8. Williams D.O., Selzer F., Johnston J.M., Kelsey S.F., Jacobs A., Laskey W.K., Detre K.M. Repeat revascularization in the stent era: a report from the NHLBI dynamic registry. Circulation. 104:2001;11-387.
9. Lansky A.J., Roubin G.S., O'Shaughnessy C.D., Moore P.B., Dean L.S., Raizner A.E., Safian R.D., Zidar J.P., Kerr J.L., Popma J.J., Mehran R., Kuntz R.E., Leon M.B. Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation. 102:2000;1364-1368.
10. Kastrati A., Schomig A., Elezi S., Schuhlen H., Dirschinger J., Hadamitzky M., Wehinger A., Hausleiter J., Walter H., Neumann F.J. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 30:1997;1428-1436.
11. Dussaillant G.R., Mintz G.S., Pichard A.D., Kent K.M., Satler L.F., Popma J.J., Wong S.C., Leon M.B. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol. 26:1995;720-724.
12. Hoffmann R., Mintz G.S., Dussaillant G.R., Popma J.J., Pichard A.D., Satler L.F., Kent K.M., Griffin J., Leon M.B. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 94:1996;1247-1254.
13. Edelman E.R., Rogers C. Pathobiologic responses to stenting. Am J Cardiol. 81:1998;4E-6E.
14. Komatsu R., Ueda M., Naruko T., Kojima A., Becker A.E. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 98:1998;224-233.
15. Prati F., Di Mario C., Moussa I., Reimers B., Mallus M.T., Parma A., Lioy E., Colombo A. In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation. 99(8):1999;1011-1014.
16. Teirstein P.S., Massullo V., Jani S., Popma J.J., Mintz G.S., Russo R.J., Schatz R.A., Guarneri E.M., Steuterman S., Morris N.B., Leon M.B., Tripuraneni P. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 336:1997;1697-1703.
17. Waksman R., White R.L., Chan R.C., Bass B.G., Geirlach L., Mintz G.S., Satler L.F., Mehran R., Serruys P.W., Lansky A.J., Fitzgerald P., Bhargava B., Kent K.M., Pichard A.D., Leon M.B. Intracoronary radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 101:2000;2165-2171.
18. Leon M.B., Teirstein P.S., Moses J.W., Tripuraneni P., Lansky A.J., Jani S., Wong S.C., Fish D., Ellis S., Holmes D.R., Kerieakes D., Kuntz R.E. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 344:2001;250-256.
19. Sriram V., Patterson C. Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery. Circulation. 103:2001;2414-2419.
20. Waksman R., Bhargava B., Mintz G.S., Mehran R., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Leon M.B. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol. 36:2000;65-68.
21. Waksman R., Ajani A.E., White R.L., Pinnow E., Cheneau E., Leborgne L., Dieble R., Bui A.B., Satler L.F., Pichard A.D., Kent K.K., Lindsay J. Twelve versus six months of clopidogrel to reduce cardiac major events in patients undergoing gamma radiation therapy for in-stent restenosis: WRIST 12 VS. WRIST PLUS. Circulation. 106(7):2002;776-778.
22. Marx S.O., Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 104:2001;852-855.
23. Saunders R.N., Metcalfe M.S., Nicholson M.L. Rapamycin in transplantation: a review of the evidence. Kidney Int. 59:2001;3-16.
24. Cao W., Mohacsi P., Shorthouse R., Pratt R., Morris R.E. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 59:1995;390-395.
25. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 98:1996;2277-2283.
26. Farb A., John M., Acampo E., Kolodgie F.D., Prescott M.F., Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation. 106:2002;2379-2384.
27. Wani M.C., Taylor H.I., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents VI. The isolation and structure of taxol, a novel antiluekmic and antitumor agents from Taxus brevifolia. J Am Chem Soc. 93:1971;2325-2327.
28. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N Engl J Med. 332:1995;1004-1014.
29. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
30. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., Wild D.H., Brehm B.R., Riessen R., Koveker G., Karsch K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in-vitro and in-vivo using local drug delivery. Circulation. 96:1997;636-645.
31. Gobeil F., Laflamme M., Bouchard M., Campbell E., Wood M., St-Jacques P., Vincent J., Leclerc G. Biodivysio stent coated with metaloproteinase inhibitor reduces neointimal hyperplasia in a porcine coronary artery restenosis model. Circulation. 104:2001;11-388.
32. de Scheerder L., Wang K., Wliczek K., van Dorpe J., Verbeken E., Desmet W., Schacht E., Piessens J. Local methylprednisolone inhibition of foreign body response to coated intracoronary stents. Coron Artery Dis. 7:1996;161-166.
33. Fauci A.S., Dale D.C., Balow J.E. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 84:1976;304-314.
34. Lincoff A.M., Furst J.G., Ellis S.G., Tuch R.J., Topol E.J. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 29:1997;808-816.
35. Lee C.W., Chae J.K., Lim H.Y., Hong M.K., Kim J.J., Park S.W., Park S.J. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J. 138:1999;60-63.
36. Villa A.E., Guzman L.A., Chen W., Golomb G., Levy R.J., Topol E.J. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest. 93:1994;1243-1249.
37. Kutryk M.J., Foley D.P., van den Brand M., Hamburger J.N., van der Giessen W.J., deFeyter P.J., Bruining N., Sabate M., Serruys P.W. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol. 39:2002;281-287.
38. Klugherz B.D., Jones P.L., Cui X., Chen W., Meneveau N.F., DeFelice S., Connolly J., Wilensky R.L., Levy R.J. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol. 18:2000;1181-1184.
39. Van Belle E., Tio F.O., Couffinhal T., Maillard L., Passeri J., Isner J.M. Stent endothelialization: time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation. 95:1997;438-448.
40. Van Belle E., Tio F.O., Chen D., Maillard L., Chen D., Kearney M., Isner J.M. Passivation of metallic stents following arterial gene transfer of phVEGF 165inhibits thrombus formation and intimal thickening. J Am Coll Cardiol. 29:1997;1371-1379.
41. Asahara T., Bauters C., Pastore C.J., Kearney M., Rossow S., Bunting S., Ferrara N., Symes J.F., Isner J.M. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 91:1995;2793-2801.
42. Chandrasekar B., Tanguay J.F. Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model. J Am Coll Cardio. 36:2000;1972-1978.
43. Yokoi H., Daida H., Kuwabara Y., Nishikawa H., Takatsu F., Tomihara H., Nakata Y., Kutsumi Y., Ohshima S., Nishiyama S., Seki A., Kato K., Nishimura S., Kanoh T., Yamaguchi H. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 30:1997;855-862.
44. Tardif J.C., Cote G., Lesperance J., Bourassa M., Lambert J., Doucet S., Bilodeau L., Nattel S., de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 337:1997;365-372.
45. Tamai H., Katoh O., Suzuki S., Fujii K., Aizawa T., Takase S., Kurogane H., Nishikawa H., Sone T., Sakai K., Suzuki T. Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am Heart J. 138:1999;968-975.
46. Holmes D.R., Savage M., LaBlanche J.M., Grip L., Serruys P.W., Fitzgerald P., Fischman D., Goldberg S., Brinker J.A., Zeiher A.M., Shapiro L.M., Willerson J., Davis B.R., Ferguson J.J., Popma J., King S.B., Lincoff A.M., Tcheng J.E., Chan R., Granett J.R., Poland M. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 106:2002;1243-1250.
47. De Scheerder L., Wilczek K., Van Dorpe J., Verbeken E., Cathapermal S., Wang K., Desmet W., Schacht E., Foegh M., De Geest H., Piessens J. Local angiopeptin delivery using coated stents reduces neointimal proliferation in overstretched porcine coronary arteries. J Invasive Cardiol. 8:1996;215-222.
48. Emanuelsson H., Beatt K.J., Bagger J.P., Bagger J.P., Balcon R., Heikkila J., Piessens J., Schaeffer M., Suryapranata H., Foegh M. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. Circulation. 91:1995;1689-1696.
49. Rogers C., Edelman E.R. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 91:1995;2995-3001.
50. Rogers C.D.K. Drug eluting stents: role of stent design, delivery vehicle, and drug selection. Rev Cardiovasc Med. 3(Suppl 5):2002;S16-S22.
51. Hehrlein C., Zimmermann M., Metz J., Ensinger W., Kubler W. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron Artery Dis. 6:1995;581-586.
52. Garasic J.M., Edelman E.R., Squire J.C., Seifert P., Williams M.S., Rogers C. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation. 101:2000;812-818.
53. Kastrati A., Dirschinger J., Boekstegers P., Elezi S., Schuhlen H., Pache J., Steinbeck G., Schmitt C., Ulm K., Neumann F.J., Schomig A. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of 5 stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 50:2000;290-297.
54. Kastrati A., Mehilli J., Dirschinger J., Dotzer F., Schuhlen H., Neumann F.J., Fleckenstein M., Pfafferott C., Seyfarth M., Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO 1) trial. Circulation. 103:2001;2816-2821.
55. Kastrati A., Schomig A., Dirschinger J., Mehilli J., von Welser N., Pache J., Schuhlen H., Schilling T., Schmitt C., Neumann F.J. Increased risk of restenosis after placement of gold-coated stents. Results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation. 101:2000;2478-2483.
56. Silber S., Reifart N., Morice M-C, Vom Dahl J., Benitz E., Hauptman K-E, Sousa J.E., Webb J.G., Kaul U., Chan C. The Nugget trial (NIR ultimate gold-gilded equivalency trial): 6 months post-procedure safety and efficacy results. Circulation. 104:2001;11-623.
57. Windecker S., Mayer L., De Pasquale G., Maier W., Dirsch O., De Groot P., Wu Y.P., Noll G., Leskosek B., Meier B., Hess O.M. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation. 104:2001;928-933.
58. Edelman E.R., Seifert P., Groothuis A., Morss A., Bornstein D., Rogers C. Gold-coated NIR stents in porcine coronary arteries. Circulation. 103:2001;429-434.
59. Whelan D.M., van der Giessen W.J., Krabbendam S.C., van Vliet E.A., Verdouw P.D., Serruys P.W., van Beusekom H.M. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart. 83:2000;338-345.
60. McKenna C.J., Camrud A.R., Sangiorgi G., Kwon H.M., Edwards W.D., Holmes D.R., Schwart R.S. Fibrin-film stenting in a porcine coronary injury model: efficacy and safety compared with uncoated stents. J Am Coll Cardiol. 31:1998;1434-1438.
61. van der Giessen W.J., Lincoff A.M., Schwartz R.S., van Beusekom H.M., Serruys P.W., Holmes D.R., Ellis S.G., Topol E.J. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation. 94:1996;1690-1697.
62. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., Komori H., Tsuji T., Motohara S., Uehata H. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation. 102:2000;399-404.
63. Hill-West J.L., Chowdhury S.M., Slepian M.J., Hubbell J.A. Inhibition of thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel barriers. Proc Natl Acad Sci U S A. 91:1994;5967-5971.
64. West J.L., Hubbell J.A. Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing. Proc Natl Acad Sci U S A. 93(4):1996;13188-13193.
65. Yu J., Lamba N.M., Courtney J.M., Whateley T.L., Gaylor J.D., Lowe G.D., Ishihara K., Nakabayashi N. Polymeric biomaterials: influence of phosphorylcholine polar groups on protein adsorption and complement activation. Int J Artif Organs. 17:1994;499-504.
66. Gunn J., Cumberland D. Stent coatings and local drug delivery; state of the art. Eur Heart J. 20:1999;1693-1700.
67. Robinson K.A., Chronos N.A.F., Royal J., Suh L., Cipolla G.D., Virmani R., Stack R.S. Actinomycin-D drug eluting stents preserve lumen size and inhibit fibrocellular neointima in pig coronary arteries. Circulation. 104:2001;11-506.
68. Gallo R., Padurean A., Jayaraman T., Marx S., Roque M., Adelman S., Chesebro J., Fallon J., Fuster V., Marks A., Badimon J.J. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 99:1999;2164-2170.
69. Burke S.E., Lubbers N.L., Chen Y.W., Hsieh G.C., Mollison K.W., Luly J.R., Wegner C.D. Neointimal formation after balloon-induced vascular injury in Yucatan mini pigs is reduced by oral rapamycin. J Cardiovasc Pharmacol. 33:1999;829-835.
70. Suzuki T., Kopia G., Hayashi S., Hayashi S., Bailey L.R., Llanos G., Wilensky R., Klugherz B.D., Papandreou G., Narayan P., Leon M.B., Yeung A.C., Tio F., Tsao P.S., Falotico R., Carter A.I. Stent-based delivery of sirolirnus reduces neointitnal formation in a porcine coronary model. Circulation. 104:2001;1188-1193.
71. Klugherz B.D., Ilanos G., Lieuallen W., Kopia G.A., Papandreou G., Narayan P., Sasseen B., Adelman S.J., Falotico R., Wilensky R.L. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 13:2002;183-188.
72. Sollott S.J., Cheng L., Pauly R.R., Jenkins G.M., Monticone R.E., Kuzuya M., Froehlich J.P., Crow M.T., Lakatta E.G., Rowinsky E.K. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 95:1995;1869-1876.
73. Drachman D.E., Edelman E.R., Seifert P., Groothuis A.R., Bornstein D.A., Kamath K.R., Palasis M., Yang D., Nott S.H., Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 36:2000;2325-2332.
74. Heldman A.W., Cheng L., Jenkins G.M., Heller P.F., Kim D.W., Ware M., Nater C., Hruban R.H., Rezai B., Abella B.S., Bunge K.E., Kinsella J.L., Sollott S.J., Lakatta E.G., Brinker J.A., Hunter W.L., Froehlich J.P. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 103:2001;2289-2295.
75. Farb A., Heller P.F., Shroff S., Cheng L., Kolodgie F.D., Carter A.J., Scott D.S., Froehlich J., Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 104:2001;473-479.
76. Sousa J.E., Costa M.A., Abizaid A., Abizaid A., Abizaid A.S., Feres F., Pinto I.M., Seixas A.C., Staico R., Mattos L.A., Sousa A.G., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 103:2001;192-195.
77. Sousa J.E., Costa M.A., Abizaid A.C., Rensing B.J., Abizaid A.S., Tanajura L.F., Kozuma K., Van Langenhove G., Sousa A.G., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 104:2001;2007-2011.
78. Sousa J.E., Costal M.A., Sousa AGMR, Abizaid A.C., Seixas A.C., Abizaid A.S., Feres F., Mattos L.A., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Two-year angiographic and intravascular ultrasound follow-up after implantation of Sirolimus-eluting stents in human coronary arteries. Circulation. 107:2003;381-383.
79. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780.
80. Curfrman G.D. Sirolirmus-eluting coronary stents. N Engl J Med. 346:2002;1770-1771.
81. Serruys P.W., Degertekin M., Tanabe K., Abizaid A., Sousa J.E., Colombo A., Guagliumi G., Wijns W., Lindeboom W.K., Ligthart J., de Feyter P.J., Morice M.C. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 106:2002;798-803.
82. Moses JW, Leon, MB, Popma JJ, et al. SIRIUS: a US multicenter, randomized, double-blind study of the SIRolimUS-eluting stent in de novo native coronary lesions. Presented at the Transcatheter Cardiovascular Therapeutics Conference, September 2002, Washington, DC.
83. Sousa J.E., Costal M.A., Abizaid A., Sousa A.G., Feres F., Mattos L.A., Centemero M., Maldonado G., Abizaid A.S., Pinto I., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Sirolimus-eluting stent for the treatment of in-stent restenosis a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 107:2003;24-27.
84. Degertekin M., Regar E., Tanabe K., Smits P.C., van der Giessen W.J., Carlier S.G., de Feyter P., Vos J., Foley D.P., Ligthart J.M., Popma J.J., Serruys P.W. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. JACC. 41(2):2003;184-189.
85. Airoldi F., Di Mario C., Stankovic Get al. Bifurcational coronary artery treatment with rapamycine-eluting stent: results from a single-center experience in the first 50 cases. Am J Cardiol. 90(Suppl 6A):2002;5H.
86. Grube E. The SCORE trial. Presented at the European Paris Course on Revascularization, May 2001, Paris, France.
87. Kataoka T., Grube E., Honda Y., Morino Y., Hur S.H., Bonneau H.N., Colombo A., Di Mario C., Guagliumi G., Hauptmann K.E., Pitney M.R., Lansky A.J., Stertzer S.H., Yock P.G., Fitzgerald P.J. 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation. 106:2002;1788-1793.
88. Grube E., Silber S.M., Hauptrnann K.E. Taxus 1: prospective, randomized, double-blind comparison of NlR stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls. Circulation. 104:2001;11-463.
89. Columbo A. TAXUS-II international study cohort II: moderate-release formulation - six-month results intent to treat analysis. Presented at the Transcatheter Cardiovascular Therapeutics Conference, September 2002, Washington, DC.
90. Columbo A. TAXUS-II international study cohort I: slow-release formulation - six-month results intent to treat analysis. Presented at the Transcatheter Cardiovascular Therapeutics Conference, September 2002, Washington, DC.
91. Stone G. Safety and performance of a paclitaxel-eluting stent for the treatment of in-stent restenosis: preliminary results of the TAXUS-III trial. Presented at the American College of Cardiology Conference, March 19, 2002, Atlanta, GA.
92. Park S.J., Shim V.I.H., Ho D.S., Raizner A.E., Park S.W., Kim J.J., Hong M.K., Lee C.W., Cho S.Y., Jang Y.S., Choi D.H., Pak Lau C-P, Lam R., Wang Y. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT trial. Circulation. 104:2001;11-464.
93. Park SJ. Six-month results of ASPECT. Presented by Alan Heldman (on behalf of SJ Park) at the Transcatheter Cardiovascular Therapeutics Conference, September 2001, Washington, DC.
94. Park S., Shim W.H., Ho D., Raizner A.E. Long-term follow-up in the ASPECT clinical study. Am I Cardiol. 90(Suppl 6A):2002;IH.
95. Gershlick A.H., Descheerder L., Chevalier B., Camenzind E., Gommeaux A., Vrints C., Reifart N., Missault L., Goy J-J, Brinker J.A., Stephens-Lloyd A., Heldman A.W. Local drug delivery to inhibit coronary artery restenosis. Data from the ELUTES (EvaLUation of paclitaxel Eluting Stent) clinical trial. Circulation. 104:2001;11-416.
96. Gershlick A., De Scheerder L., Chevalier B. Long-term follow-up in the ELUTES clinical study. Am J Cardiol. 90(Suppl 6A):2002;IH.
97. Serruys PW for the ACTION Trial Investigators. Presented at the ESC Berlin, September 2002.
98. Knopf W for the DELIVER Investigators. DELIVER: a US multicenter, randomized, single-blind study of the ACHIEVE drug coated coronary stent system in the treatment of patients with de novo native coronary lesions. Presented at the Cardiovascular Revascularization Therapy, January 27, 2002, Washington, DC.
99. Cutlip D.E., Chauhan M.S., Baim D.S., Ho K.K., Popma J.J., Carrozza J.P., Cohen D.J., Kuntz R.E. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 40:2002;2082-2089.
100. Liistro F., Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 86:2001;262-264.